Company intelligence / Profile preview

TA Sciences

New York City, New York, United States

Ownership: Private
Employees: ~26
Development stage: Other

Overview

TA Sciences’ lead compound, TA-65®, has demonstrated in double-blind, placebo-controlled human clinical trials the ability to lengthen telomeres and improve immune health, reduce inflammation following myocardial infarction, and improve cardiovascular markers in metabolic syndrome. The compound is Generally Recognized as Safe and has shown efficacy and safety across more than a decade of clinical data

Therapeutic areas: CardiovascularOtherImmunologyMetabolic Disorders
Modalities: Small moleculePlant-based compound
Industry: Biotech

Drug pipeline

2 assets

cycloastragenol

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Collaborations with academic centers (e.g., University of Texas Southwestern, Newcastle University, Harvard University)

Beyond the preview

Go deeper on TA Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TA Sciences.

Explore the full profile